Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

<p>ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRAS As of the April 25, 2023 data cut-off date, among the 22 evaluable patients, preliminary data from the trial suggest that those with greater than median T cell response had not reached median Relapse-Free Survival compared […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/elicio-therapeutics-presents-updated-preliminary-data-including-promising-relapse-free-survival-data-from-the-phase-1-study-of-eli-002-at-aacr-special-conference-pancreatic-cancer/">Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>